High affinity ligands
(HAL) – D-Peptides as new
drug generation

Cost-effective, tailor-made, innovative drugs

COSMIX is about helping people develop the therapies the need to treat disease an illness in the future.The unique fusion of two proprietary technologies bring efficiency and accuracy to drug development for the next generation of therapeutics, D-peptide based drugs called HAL (High Affinity Ligands).

For its HAL Therapeutics business COSMIX combines two technologies: mRNA-Display and Chemical Protein Synthesis (CPS).
This proprietary platform generates unique HAL which overcome the shortcomings of peptide drugs of the past.

COSMIX believes that its D-peptide technology, producing HALs that are D-stereoisomers rather than the natural L-form, has the potential to overcome the problems facing antibody-based therapeutics and is a leading candidate for the next generation of monoclonal antibody products.

In a first step a mirror image of the target consisting entirely of D-amino acids is generated using CPS technology.

In a second step L-peptides binding tightly to the mirror image target are identified using mRNA display technology.

Then the identified L-peptides are synthesized with D-amino acids and binding of HAL to the L-target is confirmed.